Company intelligence / Profile preview

Minerali

Radnor, Pennsylvania, United Statesmineraliindustriali.it ↗

Ownership: Private
Employees: ~41
Development stage: Other

Overview

Lorundrostat, a highly selective aldosterone synthase inhibitor, has demonstrated statistically significant and clinically meaningful reductions in blood pressure in multiple clinical trials. Positive topline results were reported from both the pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials for uncontrolled or resistant hypertension. The drug showed a favorable safety and tolerability profile across studies, supporting its potential regulatory approval and commercial value[7].

Therapeutic areas: PulmonologyCardiovascularNephrology
Modalities: Small molecule
Industry: Biotech

Partnerships

Mitsubishi Tanabe Pharma Corporation (licensor of lorundrostat)[3][6]Cleveland Clinic research teams participated in clinical trials[7]

Beyond the preview

Go deeper on Minerali.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Minerali.

Explore the full profile